Symbols / BNGO $1.16 -3.33% Bionano Genomics, Inc.
BNGO Chart
About
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for analysis and interpretation of genomic data from microarray and sequencing data for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Instruments & Su | Market Cap | 12.87M |
| Enterprise Value | 10.94M | Income | -26.39M | Sales | 28.51M |
| Book/sh | 4.14 | Cash/sh | 1.74 | Dividend Yield | — |
| Payout | 0.00% | Employees | 95 | IPO | — |
| P/E | — | Forward P/E | -1.05 | PEG | — |
| P/S | 0.45 | P/B | 0.28 | P/C | — |
| EV/EBITDA | -0.46 | EV/Sales | 0.38 | Quick Ratio | 1.07 |
| Current Ratio | 1.98 | Debt/Eq | 38.03 | LT Debt/Eq | — |
| EPS (ttm) | -4.85 | EPS next Y | -1.11 | EPS Growth | — |
| Revenue Growth | -2.60% | Earnings | 2026-05-13 | ROA | -27.74% |
| ROE | -66.15% | ROIC | — | Gross Margin | 46.25% |
| Oper. Margin | -107.36% | Profit Margin | -92.59% | Shs Outstand | 11.09M |
| Shs Float | 9.96M | Short Float | 10.15% | Short Ratio | 10.74 |
| Short Interest | — | 52W High | 5.50 | 52W Low | 1.06 |
| Beta | 1.60 | Avg Volume | 360.17K | Volume | 112.30K |
| Target Price | $5.50 | Recom | Strong_buy | Prev Close | $1.20 |
| Price | $1.16 | Change | -3.33% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-24 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-08-18 | main | HC Wainwright & Co. | Buy → Buy | $11 |
| 2025-05-20 | up | Maxim Group | Hold → Buy | $8 |
| 2025-04-09 | init | HC Wainwright & Co. | — → Buy | $10 |
| 2025-04-02 | main | Scotiabank | Sector Perform → Sector Perform | $4 |
| 2024-11-15 | down | Ladenburg Thalmann | Buy → Neutral | — |
| 2024-05-16 | main | BTIG | Buy → Buy | $2 |
| 2024-03-07 | main | Scotiabank | Sector Outperform → Sector Outperform | $6 |
| 2023-11-13 | down | Maxim Group | Buy → Hold | — |
| 2023-08-10 | main | BTIG | Buy → Buy | $10 |
- Bionano Genomics Stock Soars As Efficiency Gains Meet Growth Story - Benzinga Mon, 23 Mar 2026 20
- BNGO Stock Price, Quote & Chart | BIONANO GENOMICS INC (NASDAQ:BNGO) - ChartMill hu, 02 Apr 2026 07
- In 211 myeloma samples, OGM found abnormalities older tests missed - Stock Titan hu, 02 Apr 2026 12
- Bionano Genomics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Sahm Sat, 21 Mar 2026 12
- Despite Fast-paced Momentum, Bionano Genomics (BNGO) Is Still a Bargain Stock - finance.yahoo.com Mon, 08 Sep 2025 07
- AI Investing Insights - Official Homepage - Intellectia AI™ - Intellectia AI Fri, 03 Apr 2026 16
- Market Cool On Bionano Genomics, Inc.'s (NASDAQ:BNGO) Revenues - simplywall.st Fri, 30 Jan 2026 08
- [ARS] Bionano Genomics, Inc. SEC Filing - Stock Titan hu, 02 Apr 2026 21
- Bionano Genomics (BNGO) Is Attractively Priced Despite Fast-paced Momentum - finance.yahoo.com Fri, 22 Aug 2025 07
- AI Investing Insights - Official Homepage - Intellectia AI™ - Intellectia AI Fri, 03 Apr 2026 17
- Bionano Genomics (NASDAQ: BNGO) outlines 2026 virtual meeting and proxy votes - Stock Titan hu, 02 Apr 2026 20
- Income Statement - Intellectia AI Fri, 03 Apr 2026 06
- At genetics summit, 12 studies use Bionano genome mapping tech - Stock Titan ue, 17 Mar 2026 07
- AI Investing Insights - Official Homepage - Intellectia AI™ - Intellectia AI Fri, 03 Apr 2026 16
- Global scientists converge online to map genomes at Bionano’s 4-day summit - Stock Titan Mon, 09 Feb 2026 08
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
28.51
-7.37%
|
30.78
-14.79%
|
36.12
+29.90%
|
27.80
|
| Operating Revenue |
|
28.51
-7.37%
|
30.78
-14.79%
|
36.12
+29.90%
|
27.80
|
| Cost Of Revenue |
|
15.32
-49.59%
|
30.40
+14.49%
|
26.55
+21.47%
|
21.86
|
| Reconciled Cost Of Revenue |
|
15.32
-49.59%
|
30.40
+14.49%
|
26.55
+21.47%
|
21.86
|
| Gross Profit |
|
13.19
+3369.74%
|
0.38
-96.03%
|
9.57
+60.91%
|
5.95
|
| Operating Expense |
|
46.52
-39.31%
|
76.66
-47.78%
|
146.79
+6.65%
|
137.64
|
| Research And Development |
|
11.37
-54.14%
|
24.80
-54.10%
|
54.03
+10.16%
|
49.05
|
| Selling General And Administration |
|
35.15
-32.21%
|
51.85
-44.10%
|
92.76
+4.70%
|
88.60
|
| Total Expenses |
|
61.85
-42.23%
|
107.05
-38.24%
|
173.34
+8.68%
|
159.50
|
| Operating Income |
|
-33.34
+56.29%
|
-76.28
+44.41%
|
-137.22
-4.20%
|
-131.70
|
| Total Operating Income As Reported |
|
-33.34
+67.94%
|
-103.98
+51.69%
|
-215.25
-63.44%
|
-131.70
|
| EBITDA |
|
-16.30
+82.91%
|
-95.39
+56.94%
|
-221.52
-83.72%
|
-120.57
|
| Normalized EBITDA |
|
-16.30
+74.65%
|
-64.30
+55.19%
|
-143.50
-19.01%
|
-120.57
|
| Reconciled Depreciation |
|
9.73
-31.60%
|
14.23
+2.26%
|
13.91
+41.38%
|
9.84
|
| EBIT |
|
-26.03
+76.25%
|
-109.61
+53.44%
|
-235.43
-80.53%
|
-130.41
|
| Total Unusual Items |
|
0.00
+100.00%
|
-31.08
+60.16%
|
-78.02
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
0.00
+100.00%
|
-31.08
+60.16%
|
-78.02
|
0.00
|
| Special Income Charges |
|
0.00
+100.00%
|
-31.08
+60.16%
|
-78.02
|
0.00
|
| Other Special Charges |
|
—
|
3.38
|
—
|
—
|
| Impairment Of Capital Assets |
|
0.00
-100.00%
|
19.68
-74.53%
|
77.28
|
0.00
|
| Restructuring And Mergern Acquisition |
|
0.00
-100.00%
|
8.02
+982.59%
|
0.74
|
—
|
| Net Income |
|
-26.39
+76.44%
|
-112.02
+51.82%
|
-232.49
-75.34%
|
-132.60
|
| Pretax Income |
|
-26.33
+76.49%
|
-111.98
+51.82%
|
-232.43
-77.82%
|
-130.71
|
| Net Non Operating Interest Income Expense |
|
4.60
+217.60%
|
-3.91
+77.06%
|
-17.04
-1509.26%
|
1.21
|
| Interest Expense Non Operating |
|
0.30
-87.44%
|
2.37
+179.13%
|
-3.00
-1106.38%
|
0.30
|
| Net Interest Income |
|
4.60
+217.60%
|
-3.91
+77.06%
|
-17.04
-1509.26%
|
1.21
|
| Interest Expense |
|
0.30
-87.44%
|
2.37
+179.13%
|
-3.00
-1106.38%
|
0.30
|
| Interest Income Non Operating |
|
4.89
+132.98%
|
2.10
-36.54%
|
3.31
+119.71%
|
1.51
|
| Interest Income |
|
4.89
+132.98%
|
2.10
-36.54%
|
3.31
+119.71%
|
1.51
|
| Other Income Expense |
|
2.41
+107.59%
|
-31.80
+59.32%
|
-78.17
-34953.36%
|
-0.22
|
| Other Non Operating Income Expenses |
|
2.41
+437.15%
|
-0.72
-383.78%
|
-0.15
+33.63%
|
-0.22
|
| Tax Provision |
|
0.07
+103.03%
|
0.03
-46.77%
|
0.06
-96.71%
|
1.88
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
+100.00%
|
-6.53
+60.16%
|
-16.38
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-26.39
+76.44%
|
-112.02
+51.82%
|
-232.49
-75.34%
|
-132.60
|
| Net Income From Continuing Operation Net Minority Interest |
|
-26.39
+76.44%
|
-112.02
+51.82%
|
-232.49
-75.34%
|
-132.60
|
| Net Income From Continuing And Discontinued Operation |
|
-26.39
+76.44%
|
-112.02
+51.82%
|
-232.49
-75.34%
|
-132.60
|
| Net Income Continuous Operations |
|
-26.39
+76.44%
|
-112.02
+51.82%
|
-232.49
-75.34%
|
-132.60
|
| Normalized Income |
|
-26.39
+69.82%
|
-87.46
+48.81%
|
-170.86
-28.85%
|
-132.60
|
| Net Income Common Stockholders |
|
-26.39
+76.44%
|
-112.02
+51.82%
|
-232.49
-75.34%
|
-132.60
|
| Diluted EPS |
|
-4.85
+91.92%
|
-60.05
+85.30%
|
-408.60
-52.63%
|
-267.71
|
| Basic EPS |
|
-4.85
+91.92%
|
-60.05
+85.30%
|
-408.60
-52.63%
|
-267.71
|
| Basic Average Shares |
|
5.45
+191.89%
|
1.87
+227.84%
|
0.57
+14.88%
|
0.50
|
| Diluted Average Shares |
|
5.45
+191.89%
|
1.87
+227.84%
|
0.57
+14.88%
|
0.50
|
| Diluted NI Availto Com Stockholders |
|
-26.39
+76.44%
|
-112.02
+51.82%
|
-232.49
-75.34%
|
-132.60
|
| Total Other Finance Cost |
|
—
|
3.64
-84.42%
|
23.35
|
—
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
214.40
|
| Current Assets |
|
140.12
|
| Cash Cash Equivalents And Short Term Investments |
|
66.77
|
| Cash And Cash Equivalents |
|
17.95
|
| Other Short Term Investments |
|
48.82
|
| Receivables |
|
9.66
|
| Accounts Receivable |
|
9.32
|
| Gross Accounts Receivable |
|
9.80
|
| Allowance For Doubtful Accounts Receivable |
|
-0.48
|
| Accrued Interest Receivable |
|
0.34
|
| Inventory |
|
22.89
|
| Raw Materials |
|
—
|
| Work In Process |
|
—
|
| Finished Goods |
|
—
|
| Prepaid Assets |
|
4.70
|
| Restricted Cash |
|
35.12
|
| Other Current Assets |
|
0.98
|
| Total Non Current Assets |
|
74.28
|
| Net PPE |
|
32.48
|
| Gross PPE |
|
51.56
|
| Accumulated Depreciation |
|
-19.08
|
| Properties |
|
0.00
|
| Machinery Furniture Equipment |
|
2.98
|
| Other Properties |
|
44.83
|
| Leases |
|
3.75
|
| Goodwill And Other Intangible Assets |
|
33.97
|
| Goodwill |
|
0.00
|
| Other Intangible Assets |
|
33.97
|
| Other Non Current Assets |
|
7.83
|
| Total Liabilities Net Minority Interest |
|
118.25
|
| Current Liabilities |
|
100.03
|
| Payables And Accrued Expenses |
|
13.04
|
| Payables |
|
11.48
|
| Accounts Payable |
|
10.38
|
| Current Accrued Expenses |
|
1.55
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
5.03
|
| Total Tax Payable |
|
1.10
|
| Current Debt And Capital Lease Obligation |
|
2.44
|
| Current Debt |
|
69.80
|
| Other Current Borrowings |
|
69.80
|
| Current Capital Lease Obligation |
|
2.44
|
| Current Deferred Liabilities |
|
0.80
|
| Current Deferred Revenue |
|
0.80
|
| Other Current Liabilities |
|
78.34
|
| Total Non Current Liabilities Net Minority Interest |
|
18.22
|
| Long Term Debt And Capital Lease Obligation |
|
7.17
|
| Long Term Capital Lease Obligation |
|
7.17
|
| Non Current Deferred Liabilities |
|
0.15
|
| Non Current Deferred Revenue |
|
0.15
|
| Other Non Current Liabilities |
|
10.89
|
| Stockholders Equity |
|
96.16
|
| Common Stock Equity |
|
96.16
|
| Capital Stock |
|
0.00
|
| Common Stock |
|
0.00
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
0.76
|
| Ordinary Shares Number |
|
0.76
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
677.34
|
| Retained Earnings |
|
-581.21
|
| Gains Losses Not Affecting Retained Earnings |
|
0.02
|
| Other Equity Adjustments |
|
0.02
|
| Total Equity Gross Minority Interest |
|
96.16
|
| Total Capitalization |
|
96.16
|
| Working Capital |
|
40.09
|
| Invested Capital |
|
96.16
|
| Total Debt |
|
9.61
|
| Net Debt |
|
51.85
|
| Capital Lease Obligations |
|
9.61
|
| Net Tangible Assets |
|
62.19
|
| Tangible Book Value |
|
62.19
|
| Current Provisions |
|
0.39
|
| Interest Payable |
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-16.34
+76.28%
|
-68.92
+44.94%
|
-125.18
-0.29%
|
-124.82
|
| Cash Flow From Continuing Operating Activities |
|
-16.34
+76.28%
|
-68.92
+44.94%
|
-125.18
-0.29%
|
-124.82
|
| Net Income From Continuing Operations |
|
-26.39
+76.44%
|
-112.02
+51.82%
|
-232.49
-75.34%
|
-132.60
|
| Depreciation Amortization Depletion |
|
9.73
-31.60%
|
14.23
+2.26%
|
13.91
+41.38%
|
9.84
|
| Depreciation |
|
9.73
-31.60%
|
14.23
+2.26%
|
13.91
+41.38%
|
9.84
|
| Depreciation And Amortization |
|
9.73
-31.60%
|
14.23
+2.26%
|
13.91
+41.38%
|
9.84
|
| Other Non Cash Items |
|
0.44
+104.95%
|
-8.95
-154.51%
|
16.42
+1968.14%
|
0.79
|
| Stock Based Compensation |
|
4.53
-53.43%
|
9.74
-35.85%
|
15.18
-32.29%
|
22.42
|
| Provisionand Write Offof Assets |
|
—
|
—
|
—
|
0.65
|
| Asset Impairment Charge |
|
0.00
-100.00%
|
26.91
-65.17%
|
77.28
|
0.00
|
| Deferred Tax |
|
—
|
—
|
0.00
-100.00%
|
1.76
|
| Deferred Income Tax |
|
—
|
—
|
0.00
-100.00%
|
1.76
|
| Operating Gains Losses |
|
0.96
-85.08%
|
6.45
+1492.10%
|
0.41
+50.00%
|
0.27
|
| Gain Loss On Investment Securities |
|
—
|
0.01
-39.13%
|
0.02
-65.15%
|
0.07
|
| Unrealized Gain Loss On Investment Securities |
|
-5.16
+36.46%
|
-8.12
-1311.83%
|
-0.57
|
—
|
| Gain Loss On Sale Of PPE |
|
0.96
-68.54%
|
3.06
+700.52%
|
0.38
+87.25%
|
0.20
|
| Change In Working Capital |
|
0.51
-87.64%
|
4.16
+128.14%
|
-14.77
+47.13%
|
-27.94
|
| Change In Receivables |
|
-0.45
-110.82%
|
4.14
+280.27%
|
-2.30
-2.00%
|
-2.25
|
| Changes In Account Receivables |
|
-0.45
-110.82%
|
4.14
+280.27%
|
-2.30
-2.00%
|
-2.25
|
| Change In Inventory |
|
4.92
+937.48%
|
-0.59
+85.86%
|
-4.15
+82.47%
|
-23.68
|
| Change In Prepaid Assets |
|
-2.06
-230.26%
|
1.58
+30.50%
|
1.21
+137.94%
|
-3.20
|
| Change In Payables And Accrued Expense |
|
-1.95
+65.49%
|
-5.66
-25.22%
|
-4.52
-295.12%
|
2.31
|
| Change In Accrued Expense |
|
-0.58
+74.06%
|
-2.24
+11.34%
|
-2.52
-789.07%
|
0.37
|
| Change In Payable |
|
-1.37
+59.88%
|
-3.42
-71.43%
|
-2.00
-202.36%
|
1.95
|
| Change In Account Payable |
|
-1.37
+59.88%
|
-3.42
-71.43%
|
-2.00
-202.36%
|
1.95
|
| Change In Other Current Assets |
|
0.06
-98.72%
|
4.68
+193.19%
|
-5.02
-344.25%
|
-1.13
|
| Investing Cash Flow |
|
-12.75
-117.26%
|
73.84
+205.65%
|
24.16
-70.81%
|
82.77
|
| Cash Flow From Continuing Investing Activities |
|
-12.75
-117.26%
|
73.84
+205.65%
|
24.16
-70.81%
|
82.77
|
| Net PPE Purchase And Sale |
|
0.00
+100.00%
|
-0.10
+93.91%
|
-1.69
+46.72%
|
-3.17
|
| Purchase Of PPE |
|
0.00
+100.00%
|
-0.10
+93.91%
|
-1.69
+47.16%
|
-3.20
|
| Sale Of PPE |
|
—
|
—
|
0.00
-100.00%
|
0.03
|
| Capital Expenditure |
|
—
|
-0.10
+93.91%
|
-1.69
+48.79%
|
-3.30
|
| Net Investment Purchase And Sale |
|
-12.75
-117.24%
|
73.94
+187.12%
|
25.75
-77.93%
|
116.69
|
| Purchase Of Investment |
|
-241.88
-3.80%
|
-233.02
-109.43%
|
-111.26
-32.15%
|
-84.19
|
| Sale Of Investment |
|
229.13
-25.36%
|
306.96
+124.03%
|
137.02
-31.79%
|
200.89
|
| Net Business Purchase And Sale |
|
—
|
0.00
-100.00%
|
0.10
+100.31%
|
-31.34
|
| Purchase Of Business |
|
—
|
—
|
0.00
+100.00%
|
-31.34
|
| Net Intangibles Purchase And Sale |
|
—
|
—
|
0.00
+100.00%
|
-0.10
|
| Purchase Of Intangibles |
|
—
|
—
|
0.00
+100.00%
|
-0.10
|
| Net Other Investing Changes |
|
—
|
—
|
—
|
0.69
|
| Financing Cash Flow |
|
24.04
+275.66%
|
-13.69
-112.02%
|
113.81
+394.70%
|
23.01
|
| Cash Flow From Continuing Financing Activities |
|
24.04
+275.66%
|
-13.69
-112.02%
|
113.81
+394.70%
|
23.01
|
| Net Issuance Payments Of Debt |
|
-4.95
+89.71%
|
-48.06
-167.73%
|
70.95
+197191.67%
|
-0.04
|
| Issuance Of Debt |
|
0.00
-100.00%
|
18.00
-77.50%
|
80.00
|
0.00
|
| Repayment Of Debt |
|
-4.95
+92.51%
|
-66.06
-630.16%
|
-9.05
-25030.56%
|
-0.04
|
| Long Term Debt Issuance |
|
0.00
-100.00%
|
18.00
-77.50%
|
80.00
|
0.00
|
| Long Term Debt Payments |
|
-4.95
+92.51%
|
-66.06
-630.16%
|
-9.05
-25030.56%
|
-0.04
|
| Net Long Term Debt Issuance |
|
-4.95
+89.71%
|
-48.06
-167.73%
|
70.95
+197191.67%
|
-0.04
|
| Short Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Short Term Debt Payments |
|
—
|
—
|
—
|
—
|
| Net Short Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Net Common Stock Issuance |
|
31.10
-30.01%
|
44.43
-22.99%
|
57.70
+149.47%
|
23.13
|
| Proceeds From Stock Option Exercised |
|
0.01
-40.00%
|
0.01
-88.46%
|
0.13
-73.63%
|
0.49
|
| Net Other Financing Charges |
|
-2.12
+78.94%
|
-10.07
+32.68%
|
-14.96
-2489.10%
|
-0.58
|
| Changes In Cash |
|
-5.05
+42.37%
|
-8.77
-168.54%
|
12.79
+167.18%
|
-19.04
|
| Effect Of Exchange Rate Changes |
|
-0.01
-57.14%
|
-0.01
-110.77%
|
0.07
+271.05%
|
-0.04
|
| Beginning Cash Position |
|
9.57
-47.83%
|
18.35
+234.15%
|
5.49
-77.65%
|
24.57
|
| End Cash Position |
|
4.51
-52.90%
|
9.57
-47.83%
|
18.35
+234.15%
|
5.49
|
| Free Cash Flow |
|
-16.34
+76.32%
|
-69.03
+45.59%
|
-126.87
+0.97%
|
-128.12
|
| Interest Paid Supplemental Data |
|
1.67
-84.29%
|
10.65
+546.42%
|
1.65
+453.02%
|
0.30
|
| Amortization Of Securities |
|
-0.98
+25.84%
|
-1.32
-144.16%
|
-0.54
-184.48%
|
0.64
|
| Common Stock Issuance |
|
31.10
-30.01%
|
44.43
-22.99%
|
57.70
+149.47%
|
23.13
|
| Interest Paid CFO |
|
—
|
—
|
—
|
0.00
|
| Issuance Of Capital Stock |
|
31.10
-30.01%
|
44.43
-22.99%
|
57.70
+149.47%
|
23.13
|
| Sale Of Business |
|
—
|
0.00
-100.00%
|
0.10
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-K2026-03-23 View
- 8-K2026-03-23 View
- 42026-02-18 View
- 42026-02-18 View
- 42026-02-18 View
- 42026-02-18 View
- 42026-02-18 View
- 42026-02-04 View
- 42026-02-04 View
- 42026-02-04 View
- 42026-02-04 View
- 42026-02-04 View
- 8-K2026-01-12 View
- 10-Q2025-11-13 View
- 8-K2025-11-13 View
- 8-K2025-09-18 View
- 42025-09-12 View
- 42025-09-12 View
- 10-Q2025-08-14 View
- 8-K2025-08-14 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|